Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21926987 | 0.93 | CYP1A2 (0.64) | ALDH1A1HPGDMEN1KMT2AMAPK1 | |
| SCHEMBL21926392 | 0.92 | MEN1 (0.62) | ALDH1A1MEN1KMT2AMAPK1LMNA | |
| SCHEMBL21928862 | 0.92 | MGLL (0.71) | ALDH1A1MEN1KMT2ALMNAPKM | |
| SCHEMBL21928849 | 0.92 | HSD11B1 (0.71) | ALDH1A1MEN1KMT2AMAPK1LMNA | |
| SCHEMBL21926389 | 0.92 | MGLL (0.71) | ALDH1A1MEN1KMT2ALMNAPKM | |
| SCHEMBL1719734 | 0.90 | MGLL (0.68) | ALDH1A1MEN1KMT2AMGLLHSD11B1 | |
| SCHEMBL21926379 | 0.89 | ALDH1A1 (0.54) | ALDH1A1HPGDMEN1KMT2AMAPK1 | |
| SCHEMBL3723522 | 0.89 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AMAPK1LMNA | |
| SCHEMBL1520334 | 0.89 | ALDH1A1 (0.64) | ALDH1A1HPGDGLAHSD17B10USP2 | |
| SCHEMBL7232912 | 0.89 | ALDH1A1 (0.64) | ALDH1A1HPGDGLAHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | ARTAX BIOPHARMA INC. | 2020-04-30 | — | — | US | disclosed |
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | disclosed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | ALDH1A1 68/4885HPGD 83/4885MEN1 1206/4885 |
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | CD4, CD2, CCR1 | ALDH1A1 1450/4885HPGD 1870/4885MEN1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.